0000899243-21-002081.txt : 20210114 0000899243-21-002081.hdr.sgml : 20210114 20210114175400 ACCESSION NUMBER: 0000899243-21-002081 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210112 FILED AS OF DATE: 20210114 DATE AS OF CHANGE: 20210114 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: UBS Oncology Impact Fund L.P. CENTRAL INDEX KEY: 0001691428 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39856 FILM NUMBER: 21529928 BUSINESS ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-425-9200 MAIL ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Oncology Impact Fund (Cayman) Management L.P. CENTRAL INDEX KEY: 0001721036 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39856 FILM NUMBER: 21529929 BUSINESS ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6174259200 MAIL ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MPM Oncology Impact Management GP LLC CENTRAL INDEX KEY: 0001721035 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39856 FILM NUMBER: 21529930 BUSINESS ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6174259200 MAIL ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MPM Oncology Impact Management LP CENTRAL INDEX KEY: 0001687078 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39856 FILM NUMBER: 21529931 BUSINESS ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6174259200 MAIL ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cullinan Management, Inc. CENTRAL INDEX KEY: 0001789972 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 813867811 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 520 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-410-4650 MAIL ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 520 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Cullinan Oncology, LLC DATE OF NAME CHANGE: 20191001 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-01-12 0 0001789972 Cullinan Management, Inc. CGEM 0001691428 UBS Oncology Impact Fund L.P. UBS TRUSTEES (CAYMAN) LTD 5TH FL CAYMAN CORP CENTER 27 HOSPITAL GEORGE TOWN E9 KY1-1106 CAYMAN ISLANDS 0 0 1 0 0001721036 Oncology Impact Fund (Cayman) Management L.P. UBS TRUSTEES (CAYMAN) LTD 5TH FL CAYMAN CORP CENTER 27 HOSPITAL GEORGE TOWN E9 KY1-1106 CAYMAN ISLANDS 0 0 1 0 0001721035 MPM Oncology Impact Management GP LLC C/O MPM ASSET MANAGEMENT LLC 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001687078 MPM Oncology Impact Management LP C/O MPM ASSET MANAGEMENT LLC 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 Common Stock 2021-01-12 4 C 0 1136525 A 1136525 D Common Stock 2021-01-12 4 C 0 3551640 A 4688165 D Common Stock 2021-01-12 4 C 0 2276692 A 6964857 D Common Stock 2021-01-12 4 C 0 649030 A 7613887 D Common Stock 2021-01-12 4 P 0 300000 21.00 A 7913887 D Series Seed Convertible Preferred Stock 2021-01-12 4 C 0 1136525 D Common Stock 1136525 0 D Series A Convertible Preferred Stock 2021-01-12 4 C 0 3551640 D Common Stock 3551640 0 D Series B Convertible Preferred Stock 2021-01-12 4 C 0 2276692 D Common Stock 2276692 0 D Series C Convertible Preferred Stock 2021-01-12 4 C 0 649030 D Common Stock 649030 0 D Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. On January 12, 2021, OIF purchased 300,000 shares of Common Stock of the Issuer at a price of $21.00 per share pursuant to the Issuer's initial public offering. /s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP, the general partner of Oncology Impact Fund (Cayman) Management L.P., the GP of UBS Oncology Impact Fund L.P 2021-01-14 /s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP, the general partner of Oncology Impact Fund (Cayman) Management L.P. 2021-01-14 /s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC 2021-01-14 /s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP 2021-01-14